Gilead wins FDA ac­cel­er­at­ed ap­proval of se­ladel­par af­ter ac­quir­ing it in $4.3B deal

Six months af­ter buy­ing CymaBay Ther­a­peu­tics for $4.3 bil­lion, Gilead has se­cured ac­cel­er­at­ed ap­proval for se­ladel­par, the pri­ma­ry bil­iary cholan­gi­tis drug that was at the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER